
Oncology NEWS International
- Oncology NEWS International Vol 11 No 11
- Volume 11
- Issue 11
Education on Increased ICP Reduces Nursing ‘Headache’
WASHINGTON-Managing the associated neurological problems of brain tumors is a crucial issue for oncology nurses, said Karen Baumgartner, MSN, APRN, BC, advance practice nurse in the Neuro Center at M.D. Anderson Cancer Center. If nurses fail to notice the signs indicating increased intracranial pressure (ICP), neurological injury and even death can result.
WASHINGTONManaging the associated neurological problems of brain tumors is a crucial issue for oncology nurses, said Karen Baumgartner, MSN, APRN, BC, advance practice nurse in the Neuro Center at M.D. Anderson Cancer Center. If nurses fail to notice the signs indicating increased intracranial pressure (ICP), neurological injury and even death can result.
When turnover in the nursing staff left a neuro-oncology unit devoid of nurses knowledgeable in basic neurological assessment and experienced at identifying the signs and symptoms of increased intracranial pressure, an effective and convenient teaching method became imperative. A nurse-designed self-study module met the need, Ms. Baumgartner and her colleague Susan Hummel, RN, MN, CNS, reported at the Oncology Nursing Society (abstract 83) Congress.
Based on guidelines from the Brain Trauma Foundation, the module included a pretest, written instructional material, a post-test, and an evaluation form. Four experienced oncology nurses who were nonetheless new to neuro-oncology used the module in a pilot study. At pretest, the nurses correctly answered an average of only 60% of questions. After studying with the module, they averaged 90% correct. Their evaluations of the written material suggested revisions were needed to explain more specifically the pathophysiology of increased intracranial pressure. Once the module is approved for continuing education credit, it will be made available to other nurses at the facility, she said.
Articles in this issue
over 23 years ago
Zoledronic Acid Reduces SREs in Solid Tumorsover 23 years ago
Study Supports Wider Use of SLN Biopsy in Breast Cancerover 23 years ago
Minorities Less Likely Than Whites to Receive Good Pain Careover 23 years ago
Polyglutamate-Paclitaxel Controls Recurrent Ovarian Cancerover 23 years ago
9cRA Shown to Reverse Premaliagnant Changes in Ex-Smokersover 23 years ago
FDA Names New ODAC Chairover 23 years ago
Neoadjuvant Weekly Paclitaxel Effective in Advanced Breast Cancerover 23 years ago
Docetaxel Plus Gemcitabine Promising in Advanced Pancreatic Cancerover 23 years ago
Polysaccharides Unique Targets for Immunotherapyover 23 years ago
Genetic Fingerprinting Shows Distinct Sarcoma SubsetsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



































